-
S63845: A Translational MCL1 Inhibitor
2026-09-05
S63845 offers a precise way to interrogate MCL1 dependence, mitochondrial apoptosis, and treatment-persistent cancer states. This thought-leadership perspective connects mechanistic evidence with practical experimental strategy for hematological cancer research and translational model development.
-
Levofloxacin Workflows for Antibacterial and Bone Studies
2026-09-05
Levofloxacin supports mechanism-driven bacterial assays while also enabling controlled studies of osteoblast mineralization and cartilage metabolism. This guide connects practical dosing, endpoint selection, formulation, and troubleshooting for more reproducible research workflows.
-
AmpliFold Capture-and-Release for LFA Sensitivity
2026-09-04
The ChemRxiv study introduces AmpliFold, a capture-and-release architecture that improves lateral flow assay sensitivity by temporarily sequestering analyte-bound complexes before high-affinity rebinding. In a HER2 model, linker engineering, receptor-density tuning, and dual-affinity gold nanoparticles produced up to 16-fold lower limits of detection and improved performance with large nanoparticles.
-
Intravenous Cefazedone PK/PD in Pneumonia
2026-09-04
This study connected intravenous cefazedone exposure with pharmacodynamic target attainment in adults with mild to moderate community-acquired pneumonia. Its main contribution was showing that a 2 g every-12-hour regimen produced an average free-drug time above MIC of approximately 55%, while clinical and microbiological outcomes supported the regimen within the study population.
-
Faropenem Sodium: From PBP to NPT1
2026-09-03
Faropenem sodium is a penem antibiotic whose antibacterial potency and renal transporter behavior require separate experimental interpretations. This article develops a compartment-aware framework for linking PBP inhibition, microbial susceptibility, and NPT1-mediated uptake without overstating what any single assay can prove.
-
UK-5099 in Mitochondrial Immunometabolism
2026-09-03
UK-5099, also known as PF-1005023, gives researchers a practical way to test how mitochondrial pyruvate entry shapes respiration, cellular energy balance, cytokine output, and glucose homeostasis. This workflow-focused guide covers formulation, whole-blood adaptation, insulinoma assays, controls, and troubleshooting.
-
CD38 CAR Binder Structures and Affinity Tuning
2026-09-02
Cheng et al. define how the CD38 CAR binders RP02 and 028 recognize different antigen surfaces, produce different effects on CD38 enzymatic activity, and influence CAR-T cell behavior. The study shows that structure-guided affinity attenuation, exemplified by 028R103G, can reduce fratricide while preserving cytotoxicity against CD38-positive tumors.
-
CasKAS Maps CRISPR Specificity Through ssDNA
2026-09-02
CasKAS introduces a direct, sequencing-based strategy for profiling genome-wide Cas9 and dCas9 binding specificity by chemically capturing the single-stranded DNA exposed during CRISPR R-loop formation. The study shows how this approach can complement cleavage-focused assays while providing a comparatively accessible route to off-target analysis in both purified systems and cells.
-
nPEC for Dual-Loaded Liposome Efficiency
2026-09-01
The reference study compares six approaches for measuring encapsulation efficiency in liposomes carrying hydrophilic and lipophilic drugs together, then develops and validates nanoparticle exclusion chromatography coupled with HPLC for simultaneous analysis. Its main contribution is an analytical workflow that avoids pretreatment and remains applicable across several dual-loaded formulations, including an oleanolic acid–doxorubicin hydrochloride pair.
-
SERCA2 Dysfunction Drives Pulmonary Vascular Remodeling
2026-08-31
This study identifies SERCA2 dysfunction as an upstream driver of pulmonary vascular inflammation, oxidative stress, and remodeling through suppression of the PPARγ/PGC1α/Nrf2 pathway. Its genetic model and pharmacological rescue experiments connect calcium-handling failure with inflammatory recruitment and suggest a framework for testing redox-directed interventions in pulmonary hypertension research.
-
4-MUG Workflows for Lysosomal Enzyme Assays
2026-08-31
Learn how 4-Methylumbelliferyl-β-D-Glucopyranoside converts β-glucosidase and β-glucocerebrosidase activity into sensitive, plate-compatible fluorescence. This workflow guide connects assay design with GBA1 mRNA research, cell-based disease models, kinetic profiling, and practical troubleshooting.
-
Sodium dicloxacillin monohydrate in MSSA assays
2026-08-30
Build paired extracellular and intracellular MSSA assays around MIC, pH, and time-above-MIC rather than relying on a single endpoint. This workflow turns a narrow-spectrum β-lactam into a practical tool for mechanism studies, compartment-specific efficacy testing, and translational PK/PD design.
-
Etoposide (VP-16): Designing Mechanism-First Assays
2026-08-29
Etoposide (VP-16) is more than a cytotoxic positive control: it is a mechanistic probe for topoisomerase II-mediated DNA damage, repair, and apoptosis. This guide shows how to design, benchmark, and interpret mechanism-first cancer research assays using exposure, readout, and cell-context logic.
-
BCA Protein Quantification Kit: Practical Workflow
2026-08-29
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, supports sensitive total-protein measurement for dilute samples, cell lysates, and many detergent-containing biochemical preparations. It is intended for scientific research workflows only and should not be used for diagnostic, clinical, or medical testing.
-
Guanabenz Acetate: Receptor-to-Assay Logic
2026-08-28
Guanabenz Acetate is an α2-adrenergic receptor agonist for resolving subtype-dependent GPCR signaling. This article connects its receptor pharmacology with a critical assay-design framework inspired by recent stress-granule and innate-immunity research, while clearly separating evidence from hypothesis.